<?xml version='1.0' encoding='utf-8'?>
<document id="23330264"><sentence text="[Treatment of hepatitis C virus--2012: a real breakthrough]." /><sentence text="For almost a decade the standard of care (SOC) therapy in patients with chronic hepatitis C virus (HCV) infection has consisted of a 24-48 week course of pegylated interferon-alpha in combination with ribavirin"><entity charOffset="201-210" id="DDI-PubMed.23330264.s2.e0" text="ribavirin" /></sentence><sentence text=" This therapy is associated with significant adverse effects and leads to sustained virological response (SVR) in only 50% of patients with genotype 1" /><sentence text=" The development of compounds with direct antiviral activity (DAAs) against HCV genotype 1 during the past 10 years has led to the most significant breakthrough since the virus was first identified in 1989, Leading to a real revolution in the treatment of chronic HCV infection" /><sentence text=" The combination of the new DAAs with the SOC therapy has led to a significant improvement in achieving SVR in treatment-naÃ¯ve (30%), as well as in treatment-experienced patients with genotype 1 (24-64%, depending on the response to previous antiviral treatment)" /><sentence text=" In addition, treatment with DAAs enables shortening therapy in certain subgroups of patients, without compromising the SVR rate" /><sentence text=" However, the new treatment is challenging as it is associated with more severe adverse effects, complicated treatment regimens, need for frequent monitoring, drug-drug interaction, tolerance problems and development of selected resistant strains" /><sentence text=" This review updates the current information regarding DAAs, the new challenges that we will have to face and the therapeutic horizon in the near future" /><sentence text="" /></document>